Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Capital Expenditures (2016 - 2025)

Ptc Therapeutics has reported Capital Expenditures over the past 14 years, most recently at $2.4 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $2.4 million for Q4 2025, up 189.08% from a year ago — trailing twelve months through Dec 2025 was $8.9 million (up 12557.14% YoY), and the annual figure for FY2025 was $8.9 million, up 12557.14%.
  • Capital Expenditures for Q4 2025 was $2.4 million at Ptc Therapeutics, down from $3.4 million in the prior quarter.
  • Over the last five years, Capital Expenditures for PTCT hit a ceiling of $16.5 million in Q2 2023 and a floor of -$7.4 million in Q2 2024.
  • Median Capital Expenditures over the past 5 years was $5.6 million (2021), compared with a mean of $4.9 million.
  • Peak annual rise in Capital Expenditures hit 34142.86% in 2024, while the deepest fall reached 147.88% in 2024.
  • Ptc Therapeutics' Capital Expenditures stood at $8.7 million in 2021, then decreased by 1.19% to $8.6 million in 2022, then plummeted by 35.44% to $5.6 million in 2023, then plummeted by 147.88% to -$2.7 million in 2024, then surged by 189.08% to $2.4 million in 2025.
  • The last three reported values for Capital Expenditures were $2.4 million (Q4 2025), $3.4 million (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.